[
  {
    "id": "no_1",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category1/1.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category1/1.+Unmet+Needs+of+PPI.pdf",
    "categoryId" : "category1",
    "title" : "Unmet Needs of PPI",
    "content" : "Limitations of Proton Pump Inhibitors"
  },

  {
    "id": "no_1",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category2/1.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category2/2.+Value+Propositions+of+Fexuprazan.pdf",
    "categoryId" : "category2",
    "title" : "Value Propositions of Fexuprazan",
    "content" : "Six Value Propositons of Fexuprazan"
  },

  {
    "id": "no_1",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category5/1.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category5/1.+Phase+3+Clinical+Trial+Outcomes+of+Fexuprazan.pdf",
    "categoryId" : "category5",
    "title" : "Phase 3 Clinical Trial Outcomes of Fexuprazan",
    "content" : "Efficacy and Safety of Fexuprazan in Patients with Erosive Esophagitis"
  }

 ,{
    "id": "no_1",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/1.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/1.+sunwoo2018.pdf",
    "categoryId" : "category3",
    "title" : "Safety, tolerability, pharmacodynamics and pharmacokinetics\n\nof fexuprazan in healthy male subjects",
    "content" : "SUNWOO J, et al. Aliment Pharmacol Ther. 2018;48(2):206-218."
  }, {
    "id": "no_2",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/2.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/2.+Fexuprazan_1%EC%83%81(Brindging+PKPD).pdf",
    "categoryId" : "category3",
    "title" : "Pharmacodynamics and pharmacokinetics of fexuprazan in healthy subjects with different ethnicities",
    "content" : "HWANG JG, et al. Aliment Pharmacol Ther. 2020;52(11-12):1648-1657."
  }, {
    "id": "no_3",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/3.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/3.+pharmaceutics-15-00549+(2).pdf",
    "categoryId" : "category3",
    "title" : "Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan and Aspirin in Healthy Subjects",
    "content" : "Oh JJ, et al. Pharmaceutics. 2023;15(2):549."
  }, {
    "id": "no_4",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/4.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/4.+Lee+KN+et+al..pdf",
    "categoryId" : "category3",
    "title" : "Efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis",
    "content" : "Lee KN, et al. World J Gastroenterol.2022;28(44):6294-6308."
  }, {
    "id": "no_5",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/5.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/5.+Kim+GH+et+al..pdf",
    "categoryId" : "category3",
    "title" : "Efficacy and Safety of Fexuprazan in Patients with Acute or\n\nChronic Gastritis",
    "content" : "Kim GH, et al. Gut Liver. 2023."
  }, {
    "id": "no_6",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/6.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/6.+2023+ASCPT_Poster_Mar+2023_SNUH+(105).pdf",
    "categoryId" : "category3",
    "title" : "Pharmacokinetic drug interaction between fexuprazan and non-steroidal anti-inflammatory drugs in healthy subjects",
    "content" : "Poster presentation. ASCPT 124th 2023. PII-014-P."
  }, {
    "id": "no_7",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/7.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/7.+(%EC%B6%94%EA%B0%80%EC%9E%90%EB%A3%8C)Fexuprazan+poster_2023+DDW_IIT+Study.pdf",
    "categoryId" : "category3",
    "title" : "Efficacy and safety of fexuprazan according to the timing of dosing in patients with erosive esophagitis",
    "content" : "Poster presentation. DDW 54th 2023. Su1311-P."
  }, {
    "id": "no_8",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/8.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category3/8.+(%EC%B6%94%EA%B0%80%EC%9E%90%EB%A3%8C)Fexuprazan+poster_2023+DDW_DWP14012306.pdf",
    "categoryId" : "category3",
    "title" : "Phase 3, randomized controlled trial with fexuprazan vs. esomeprazole in Chinese patients with erosive esophagitis",
    "content" : "Poster presentation. DDW 54th 2023. Su1303-P."
  },

  {
    "id": "no_1",
    "thumbnail" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category4/1.+%EC%8D%B8%EB%84%A4%EC%9D%BC.png",
    "pdf" : "https://fexuclue.s3.ap-northeast-2.amazonaws.com/category4/1.+%EB%AF%B8%EA%B5%AD+%EC%86%8C%ED%99%94%EA%B8%B0%ED%95%99%ED%9A%8C_%EA%B8%80%EB%A1%9C%EB%B2%8C+%EC%A7%84%EC%B6%9C+%ED%98%84%ED%99%A9+(%ED%8E%99%EC%88%98%ED%81%B4%EB%A3%A8+%EB%A1%9C%EA%B3%A0X).pdf",
    "categoryId" : "category4",
    "title" : "Global Status of Fexuprazan",
    "content" : "Partnership and Registration"
  }
]